Cargando…

Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis

BACKGROUND: Alzheimer’s disease (AD) pathology begins several years before the clinical onset. The long preclinical phase is composed of three stages according to the 2011National Institute on Aging and Alzheimer’s Association (NIA-AA) criteria, followed by mild cognitive impairment (MCI), a feature...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parnetti, Lucilla, Chipi, Elena, Salvadori, Nicola, D’Andrea, Katia, Eusebi, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334406/ https://www.ncbi.nlm.nih.gov/pubmed/30646955 http://dx.doi.org/10.1186/s13195-018-0459-7

Ejemplares similares

Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals
por: Chipi, Elena, et al.
Publicado: (2019)

Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers
por: Gaetani, Lorenzo, et al.
Publicado: (2020)

HIV-Dementia Scale as a screening tool for the detection of subcortical cognitive deficits: validation of the Italian version
por: Montanucci, C., et al.
Publicado: (2021)

A/T/(N) Profile in Cerebrospinal Fluid of Parkinson’s Disease with/without Cognitive Impairment and Dementia with Lewy Bodies
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
por: Chiasserini, Davide, et al.
Publicado: (2017)

CSF neurochemical profile and cognitive changes in Parkinson’s disease with mild cognitive impairment
por: Paolini Paoletti, Federico, et al.
Publicado: (2023)

Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum
por: Paciotti, Silvia, et al.
Publicado: (2023)

Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2016)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

No diurnal variation of classical and candidate biomarkers of Alzheimer’s disease in CSF
por: Cicognola, Claudia, et al.
Publicado: (2016)

Cerebrospinal fluid in Alzheimer's: A precious tool
por: Parnetti, Lucilla, et al.
Publicado: (2016)

Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis
por: Menculini, Giulia, et al.
Publicado: (2021)

Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
por: Eusebi, Paolo, et al.
Publicado: (2018)

Should CSF Biomarkers Support a Routine Analysis for Early Diagnosis of Alzheimer's Disease?
por: Parnetti, Lucilla, et al.
Publicado: (2010)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Issue of Diurnal Variation
por: Cicognola, Claudia, et al.
Publicado: (2015)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Auditory electrophysiological assessments of Alzheimer’s disease and preclinical stages: protocol for a systematic review and meta-analysis
por: Tarawneh, Hadeel Y, et al.
Publicado: (2020)

Central Auditory Functions of Alzheimer’s Disease and Its Preclinical Stages: A Systematic Review and Meta-Analysis
por: Tarawneh, Hadeel Y., et al.
Publicado: (2022)

The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis
por: Paolini Paoletti, Federico, et al.
Publicado: (2021)

Neuroinflammation and Alzheimer’s Disease: A Machine Learning Approach to CSF Proteomics
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease
por: Santos, Cláudia Y., et al.
Publicado: (2018)

Measuring cognition and function in the preclinical stage of Alzheimer's disease
por: Weintraub, Sandra, et al.
Publicado: (2018)

Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer’s disease
por: Nakamura, Akinori, et al.
Publicado: (2018)

Biomarkers and Tools for Predicting Alzheimer’s Disease in the Preclinical Stage
por: Li, Tao-Ran, et al.
Publicado: (2022)

Incidence and Antiseizure Medications of Post-stroke Epilepsy in Umbria: A Population-Based Study Using Healthcare Administrative Databases
por: Costa, Cinzia, et al.
Publicado: (2022)

Clinical and Instrumental Characterization of Patients With Late-Onset Epilepsy
por: DiFrancesco, Jacopo C., et al.
Publicado: (2022)

Neuro-Immune Cross-Talk in the Striatum: From Basal Ganglia Physiology to Circuit Dysfunction
por: Mancini, Andrea, et al.
Publicado: (2021)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
por: Lantero‐Rodriguez, Juan, et al.
Publicado: (2021)

Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
por: Lanari, Alessia, et al.
Publicado: (2009)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
por: Bellomo, Giovanni, et al.
Publicado: (2020)

Systematic review protocol for assessing central auditory functions of Alzheimer’s disease and its preclinical stages
por: Jayakody, Dona M P, et al.
Publicado: (2020)

Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease
por: Eruysal, Emily, et al.
Publicado: (2019)

Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline
por: Filippi, Massimo, et al.
Publicado: (2023)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

New CSF biomarkers on the block
por: Teunissen, Charlotte E, et al.
Publicado: (2016)

Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation
por: Wojdała, Anna Lidia, et al.
Publicado: (2022)

Prevalence of preclinical Alzheimer disease: Comparison of current classification systems
por: Kern, Silke, et al.
Publicado: (2018)

Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies
por: Tambasco, Nicola, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mb4ppkr59cs1kat5mvi7n3n1ct